| 78.7 0.24 (0.31%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 94.25 | 1-year : | 97.67 |
| Resists | First : | 80.7 | Second : | 83.62 |
| Pivot price | 78.65 |
|||
| Supports | First : | 75.95 | Second : | 63.19 |
| MAs | MA(5) : | 79.16  |
MA(20) : | 78.38 |
| MA(100) : | 81.77 |
MA(250) : | 81.07 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 40.1 |
D(3) : | 43.4 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 89.18 | Low : | 68.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MDT ] has closed below upper band by 49.1%. Bollinger Bands are 2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 79.5 - 79.87 | 79.87 - 80.23 |
| Low: | 77.34 - 77.78 | 77.78 - 78.19 |
| Close: | 77.99 - 78.67 | 78.67 - 79.31 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Wed, 24 Jul 2024
With 87% institutional ownership, Medtronic plc (NYSE:MDT) is a favorite amongst the big guns - Simply Wall St
Wed, 24 Jul 2024
Is Medtronic plc's (NYSE:MDT) Stock On A Downtrend As A Result Of Its Poor Financials? - Yahoo Finance
Tue, 23 Jul 2024
Medtronic (MDT) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Mon, 22 Jul 2024
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Mon, 22 Jul 2024
Nicolet Advisory Services LLC Acquires New Shares in Medtronic plc (NYSE:MDT) - Defense World
Mon, 22 Jul 2024
Jupiter Asset Management Ltd. Reduces Stake in Medtronic plc (NYSE:MDT) - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1,280 (M) |
| Shares Float | 1,280 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 88.5 (%) |
| Shares Short | 15,220 (K) |
| Shares Short P.Month | 13,320 (K) |
| EPS | 2.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 38.29 |
| Profit Margin | 11.3 % |
| Operating Margin | 21.4 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 7.2 % |
| Qtrly Rev. Growth | 0.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 25.28 |
| EBITDA (p.s.) | 7.07 |
| Qtrly Earnings Growth | -44.5 % |
| Operating Cash Flow | 6,790 (M) |
| Levered Free Cash Flow | 5,460 (M) |
| PE Ratio | 28.51 |
| PEG Ratio | 3.4 |
| Price to Book value | 2.05 |
| Price to Sales | 3.11 |
| Price to Cash Flow | 14.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|